Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis.

Cheema HA, Abdul Rab S, Butt M, Jafar U, Shahid A, Rehman AU, Lee KY, Sahra S, Sah R

J Microbiol Immunol Infect - (-) - [2024-03-16; online 2024-03-16]

The majority of available data on molnupiravir come from an unvaccinated COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence from recent randomized controlled trials (RCTs) as well as observational studies stratified by vaccination status to determine the clinical efficacy and safety of molnupiravir in COVID-19 outpatients. We searched PubMed, Embase, the Cochrane Library, medRxiv, and from inception to November 2023. We conducted our meta-analysis using RevMan 5.4 with risk ratio (RR) as the effect measure. We included 8 RCTs and 5 observational studies in our meta-analysis. Molnupiravir reduced the risk of all-cause mortality (RR 0.28; 95% CI: 0.20-0.79, I2 = 0%) but did not decrease the hospitalization rate (RR 0.67; 95% CI: 0.45-1.00, I2 = 53%) in the overall population; in the immunized population, no benefits were observed. Molnupiravir lowered the rate of no recovery (RR 0.78; 95% CI: 0.76-0.81, I2 = 0%) and increased virological clearance at day 5 (RR 2.68; 95% CI: 1.94-4.22, I2 = 85%). There was no increase in the incidence of adverse events. Molnupiravir does not decrease mortality and hospitalization rates in immunized patients with COVID-19. However, it does shorten the disease course and increases the recovery rate. The use of molnupiravir will need to be considered on a case-by-case basis in the context of the prevailing social circumstances, the resource setting, drug costs, and the healthcare burden.

Category: Health

Category: Vaccines

Type: Journal article

PubMed 38555274

DOI 10.1016/j.jmii.2024.03.002

Crossref 10.1016/j.jmii.2024.03.002

pii: S1684-1182(24)00048-3

Publications 9.5.0